NeoGenomics (NASDAQ: NEO) reported Q1 EPS of $0.00, $0.01 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $168 million versus the consensus estimate of $171.35 million.

GUIDANCE:

NeoGenomics sees FY2025 revenue of $735-745 million, versus the consensus of $738.3 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.